Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bipolar II AND Psychosis NOS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Bipolar II AND Psychosis NOS. Displaying page 1 of 1.
    EudraCT Number: 2015-000465-31 Sponsor Protocol Number: CannaBiD Start Date*: 2016-06-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression
    Medical condition: Bipolar disorder, current episode depressed
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    19.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    19.0 10037175 - Psychiatric disorders 10026756 Manic depressive illness LLT
    19.0 10037175 - Psychiatric disorders 10026755 Manic depressive LLT
    19.0 10037175 - Psychiatric disorders 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-018195-33 Sponsor Protocol Number: D1443L00079 Start Date*: 2010-05-11
    Sponsor Name:Centro de Investigación Biomédica en Red en el Área de Salud Mental (CIBERSAM)
    Full Title: Eficacia de quetiapina de liberación prolongada vs. placebo como terapia coadyuvante al tratamiento eutimizante en el control de los síntomas subsindrómicos del trastorno bipolar
    Medical condition: Terapia coadyuvante en el control de los síntomas subsindrómicos del trastorno bipolar
    Disease: Version SOC Term Classification Code Term Level
    11 10057667 Trastorno  bipolar LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002778-30 Sponsor Protocol Number: GR-2018-12367476 Start Date*: 2022-01-12
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Efficacy and safety of memantine as antimanic and mood-stabilizing medication for adolescents with Bipolar Disorder: a multi-center, randomized, double-blind, placebo-controlled clinical trial
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003803-31 Sponsor Protocol Number: PIO-BP Start Date*: 2015-05-29
    Sponsor Name:Hospital Universitario Araba (Sede Santiago)
    Full Title: Adjunct pioglitazone IN THE TREATMENT OF BIPOLAR DISORDER.
    Medical condition: Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10004938 Bipolar disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004746-81 Sponsor Protocol Number: Start Date*: 2009-07-20
    Sponsor Name:Parnassia-BAVO groep [...]
    1. Parnassia-BAVO groep
    2. St. Elisabeth Ziekenhuis
    3. University Medical Center Utrecht
    Full Title: Effect of amiloride on lithium-induced chronic nephropathy. Comparing discontinuation of lithium treatment to adding amiloride while continuing lithium treatment.
    Medical condition: Renal failure due to long-term use of lithium salts in patients with bipolar disorders.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004938 Bipolar disorders HLT
    9.1 10009121 Chronic renal failure worsened LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004023-24 Sponsor Protocol Number: PRETEC-EPO Start Date*: 2016-12-15
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet
    Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO)
    Medical condition: Bipolar disorder and unipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000862-14 Sponsor Protocol Number: A-bipolar Start Date*: 2021-07-08
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC),
    Full Title: Effects of low dose Aspirin in bipolar disorder – a randomized controlled trial (the A-Bipolar RCT)
    Medical condition: Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004935 Bipolar affective disorder, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001337-40 Sponsor Protocol Number: BXCL501-105 Start Date*: 2021-10-05
    Sponsor Name:BioXcel Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER
    Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039629 Schizophrenia childhood LLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2018-002263-26 Sponsor Protocol Number: P180101 Start Date*: 2019-05-13
    Sponsor Name:DRCI APHP
    Full Title: Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder
    Medical condition: Adult individuals with bipolar I disorders who initiate lithium treatment based on the decision of themselves and their clinician
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Completed) DE (Prematurely Ended) DK (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002093-34 Sponsor Protocol Number: NW-3509/020/III/2021 Start Date*: 2021-11-12
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre...
    Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 09:57:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA